Related Experiment Video

Updated: Aug 25, 2026

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
11:24

Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy

Published on: October 18, 2011

Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas?

Michele Reni, Andrés J M Ferreri

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |March 17, 2004
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
    08:54

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

    Published on: May 8, 2018

    Related Experiment Videos

    Last Updated: Aug 25, 2026

    Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
    11:24

    Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy

    Published on: October 18, 2011

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
    08:54

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

    Published on: May 8, 2018

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

    Blood advances·2026

    High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

    Lancet (London, England)·2026

    Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

    Blood advances·2026

    SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

    Clinical lymphoma, myeloma & leukemia·2026

    Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

    Lancet (London, England)·2026

    Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

    Cancers·2026

    Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Clinical Practice Guideline for Systemic Antibacterial and Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Cell Transplant Recipients: 2026 Update.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us